Vancomic

Vancomic may be available in the countries listed below.

Ingredient matches for Vancomic

Propiverine

Propiverine hydrochloride (a derivative of Propiverine) is reported as an ingredient of Vancomic in the following countries:

• Japan

International Drug Name Search

Angiolong

Angiolong may be available in the countries listed below.

Ingredient matches for Angiolong

Diltiazem

Diltiazem hydrochloride (a derivative of Diltiazem) is reported as an ingredient of Angiolong in the following countries:

• Brazil

Isosorbide Dinitrate

Isosorbide Dinitrate is reported as an ingredient of Angiolong in the following countries:

• China

International Drug Name Search

Heafusine

Heafusine may be available in the countries listed below.

Ingredient matches for Heafusine

Hetastarch

Hetastarch is reported as an ingredient of Heafusine in the following countries:

• France

International Drug Name Search

Hytinic

In the US, Hytinic (iron polysaccharide systemic) is a member of the drug class iron products and is used to treat Iron Deficiency Anemia.

US matches:

• Hytinic

Ingredient matches for Hytinic

Polyferose

Polyferose is reported as an ingredient of Hytinic in the following countries:

• United States

International Drug Name Search

Sefdene

Sefdene may be available in the countries listed below.

Ingredient matches for Sefdene

Piroxicam

Piroxicam is reported as an ingredient of Sefdene in the following countries:

• Singapore

International Drug Name Search

Tetracyclin Wolff

Tetracyclin Wolff may be available in the countries listed below.

Ingredient matches for Tetracyclin Wolff

Tetracycline

Tetracycline hydrochloride (a derivative of Tetracycline) is reported as an ingredient of Tetracyclin Wolff in the following countries:

• Germany


• Hungary

International Drug Name Search

Bomacaine

Bomacaine may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Bomacaine

Lidocaine

Lidocaine hydrochloride (a derivative of Lidocaine) is reported as an ingredient of Bomacaine in the following countries:

• Australia

Lidocaine hydrochloride monohydrate (a derivative of Lidocaine) is reported as an ingredient of Bomacaine in the following countries:

• New Zealand

International Drug Name Search

Tismafam

Tismafam may be available in the countries listed below.

Ingredient matches for Tismafam

Famotidine

Famotidine is reported as an ingredient of Tismafam in the following countries:

• Indonesia

International Drug Name Search

Helicobacter Test Utandningstester

Helicobacter Test Utandningstester may be available in the countries listed below.

Ingredient matches for Helicobacter Test Utandningstester

Urea

Urea ?1?3C (a derivative of Urea) is reported as an ingredient of Helicobacter Test Utandningstester in the following countries:

• Denmark

International Drug Name Search

Exforge

Exforge is a brand name of amlodipine/valsartan, approved by the FDA in the following formulation(s):

EXFORGE (amlodipine besylate; valsartan - tablet; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: June 20, 2007
  
  Strength(s): EQ 10MG BASE;160MG ^[RLD], EQ 10MG BASE;320MG ^[RLD], EQ 5MG BASE;160MG, EQ 5MG BASE;320MG
  

Has a generic version of Exforge been approved?

No. There is currently no therapeutically equivalent version of Exforge available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Exforge. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Acyl compounds
  Patent 5,399,578
  Issued: March 21, 1995
  Inventor(s): Buhlmayer; Peter & Ostermayer; Franz & Schmidlin; Tibur
  Assignee(s): Ciba-Geigy Corp
  Compounds of the formula ##STR1## in which R.sub.1 is an aliphatic hydrocarbon radical which is unsubstituted or substituted by halogen or hydroxyl, or a cycloaliphatic or araliphatic hydrocarbon radical; X.sub.1 is CO, SO.sub.2, or --O--C(.dbd.O)-- with the carbon atom of the carbonyl group being attached to the nitrogen atom shown in formula I; X.sub.2 is a divalent aliphatic hydrocarbon radical which is unsubstituted or substituted by hydroxyl, carboxyl, amino, guanidino or a cycloaliphatic or aromatic radical, or is a divalent cycloaliphatic hydrocarbon radical, it being possible for a carbon atom of the aliphatic hydrocarbon radical to be additionally bridged by a divalent aliphatic hydrocarbon radical; R.sub.2 is carboxyl which, if desired, is esterified or amidated, substituted or unsubstituted amino, formyl which, if desired, is acetalized, 1H-tetrazol-5-yl, pyridyl, hydroxyl which, if desired, is etherified, S(O).sub.m --R where m is 0, 1 or 2 and R is hydrogen or an aliphatic hydrocarbon radical, alkanoyl, unsubstituted or N-substituted sulfamoyl or PO.sub.n H.sub.2 where n is 2 or 3; X.sub.3 is a divalent aliphatic hydrocarbon; R.sub.3 is carboxyl, 5-tetrazolyl, SO.sub.3 H, PO.sub.2 H.sub.2, PO.sub.3 H.sub.2 or haloalkylsulfamoyl; and the rings A and B independently of one another are substituted or unsubstituted; in free form or in salt form, can be prepared in a manner known per se and can be used, for example, as medicament active ingredients.
  
  Patent expiration dates:
  
  
  • March 21, 2012
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 21, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Solid oral dosage forms of valsartan
  Patent 6,294,197
  Issued: September 25, 2001
  Inventor(s): Wagner; Robert Frank & Katakuse; Yoshimitsu & Taike; Takashi & Yamato; Fujiki & Kohlmeyer; Manfred
  Assignee(s): Novartis AG
  The present invention is concerned with solid dosage forms comprising a) valsartan and optionally HCTZ, and b) pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods.
  
  Patent expiration dates:
  
  
  • June 18, 2017
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug product
  
  
  
  • December 18, 2017
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Method of treatment and pharmaceutical composition
  Patent 6,395,728
  Issued: May 28, 2002
  Inventor(s): Randy Lee; Webb & Marc; de Gasparo
  Assignee(s): Novartis AG
  The invention relates to a method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, myocardial infarction and its sequelae, supraventricular and ventricular arrhythmias, atrial fibrillation or atrial flutter, atherosclerosis, angina (whether stable or ustable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetessecondary aldosteronism, primary and secondary pulmonary hyperaldosteronism, primary and pulmonary hypertension, renal failure conditions, such as diabetic nephropathy,glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), and stroke, comprising administering a therapeutically effective amount of combination of (i) the AT1-antagonists valsartan or a pharmaceutically acceptable salt thereof and (ii) a Calcium channel blocker or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier to a mammal in need of such treatment and to corresponding pharmaceutical combination composition.
  
  Patent expiration dates:
  
  
  • July 8, 2019
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 23, 2011 - INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
  
  

See also...

• Exforge Consumer Information (Drugs.com)
• Exforge Consumer Information (Wolters Kluwer)
• Exforge Consumer Information (Cerner Multum)
• Exforge Advanced Consumer Information (Micromedex)
• Amlodipine/Valsartan Consumer Information (Wolters Kluwer)
• Amlodipine and valsartan Consumer Information (Cerner Multum)
• Amlodipine and valsartan Advanced Consumer Information (Micromedex)

Hifenac

Hifenac may be available in the countries listed below.

Ingredient matches for Hifenac

Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Hifenac in the following countries:

• Bangladesh

International Drug Name Search

Virusteril

Virusteril may be available in the countries listed below.

Ingredient matches for Virusteril

Acyclovir

Aciclovir is reported as an ingredient of Virusteril in the following countries:

• Greece

International Drug Name Search

Prevan

Prevan may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Prevan

Iron Dextran

Iron Dextran is reported as an ingredient of Prevan in the following countries:

• Netherlands

International Drug Name Search